# US 2021/0275555 A1 · Oligosaccharides for use in the treatment of parkinson's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275555 A1
- Document ID: US20210275555A1
- Status: Published application
- Kind: A1
- Application number: 17/259,446
- Filed: 2019-07-11
- Published: 2021-09-09
- Earliest claimed: 2018-07-11
- Assignees: Universita' Degli Studi Di Milano
- Applicants: Universita' Degli Studi Di Milano
- Inventors: Sandro SONNINO; Elena CHIRICOZZI
- Web page: https://patentgrep.com/patent/US20210275555A1

## CPC

- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/10: for petit-mal
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Oligosaccharides are for use in the treatment of neurodegenerative diseases of the central nervous system, in particular Parkinson's disease, and to pharmaceutical compositions including one or more of the oligosaccharides.

## Claims

### Claim at position 1

-15. (canceled)

### Claim 16

A method for the treatment of neurodegenerative diseases of the central nervous system comprising:
administering to a patient in need thereof of an oligosaccharide of formula (1):
R1-β-Gal-(1-3)-β-GalNAc-(1-4)-[α-Neu5Ac-(2-3)]-R2-R3 (1)
where R1 is absent or selected from α-Fuc(1-2), α-Neu5Ac-(2-3);
R2 is selected from -(1-4)-β-Gal, -(1-4)-Gal;
R3 is absent or selected from (1-4)-Glc, -(1-4)-sorbitol;
for use in the treatment.

### Claim 17 (depends on 16)

The method for the treatment of neurodegenerative diseases of the central nervous system according to claim 16, wherein said disease is selected from the group comprising: Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy, frontotemporal dementia, Lewy body dementia, Creutzfeldt-Jakob disease (CJD).

### Claim 18 (depends on 16)

The method for the treatment of neurodegenerative diseases of the central nervous system according to claim 16, wherein said oligosaccharides are selected from the group comprising:
β-Gal-(1-3)-β-GalNAc-(1-4)-[α-Neu5Ac-(2-3)]-β-Gal-(1-4)-Glc,
β-Gal-(1-3)-β-GalNAc-(1-4)-[α-Neu5Ac-(2-3)]-β-Gal-(1-4)-sorbitol,
β-Gal-(1-3)-β-GalNAc-(1-4)-[α-Neu5Ac-(2-3)]-β-Gal,
α-Fuc(1-2)-β-Gal-(1-3)-β-GalNAc-(1-4)-[α-Neu5Ac-(2-3)]-β-Gal-(1-4)-Glc,
α-Fuc(1-2)-β-Gal-(1-3)-β-GalNAc-(1-4)-[α-Neu5Ac-(2-3)]-β-Gal-(1-4)-sorbitol,
α-Fuc(1-2)-β-Gal-(1-3)-β-GalNAc-(1-4)-[α-Neu5Ac-(2-3)]--Gal,
α-Neu5Ac-(2-3)-β-Gal-(1-3)-β-GalNAc-(1-4)-[α-Neu5Ac-(2-3)]-β-Gal(1-4)-Glc,
α-Neu5Ac-(2-3)-β-Gal-(1-3)-β-GalNAc-(1-4)-[α-Neu5Ac-(2-3)]-β-Gal(1-4)-sorbitol,
α-Neu5Ac-(2-3)-β-Gal-(1-3)-β-GalNAc-(1-4)-[α-Neu5Ac-(2-3)]-Gal.

### Claim 19 (depends on 16)

The method for the treatment of neurodegenerative diseases of the central nervous system according to claim 16, comprising administering said composition intraperitoneally, subcutaneously or intravenously.

### Claim 20 (depends on 16)

The method for the treatment of neurodegenerative diseases of the central nervous system according to claim 16, wherein said treatment is continued for about 5 weeks.

### Claim 21

A pharmaceutical composition comprising one or more of the oligosaccharides of formula (1):
R1-β-Gal-(1-3)-(3-GalNAc-(1-4)-[α-Neu5Ac-(2-3)]-R2-R3 (1)
wherein R1 is absent or selected from α-Fuc(1-2), α-Neu5Ac-(2-3);
R2 is selected from -(1-4)-β-Gal, -(1-4)-Gal;
R3 is absent or selected from (1-4)-Glc, -(1-4)-sorbitol; and
one or more pharmaceutically acceptable excipients.

### Claim 22 (depends on 21)

The pharmaceutical composition according to claim 21, further comprising one or more further active principles.
